Navigation Links
AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
Date:4/4/2013

SOUTH SAN FRANCISCO, Calif., April 5, 2013 /PRNewswire/ -- AstraZeneca today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA).  OSKIRA-1 had two primary endpoints: assessing signs and symptoms of RA as measured by ACR20 response rates, and an X-ray endpoint known as mTSS (modified Total Sharp Score).

In the OSKIRA-1 study, fostamatinib achieved a statistically significant improvement in ACR20 response rate at 24 weeks in both the 100 mg twice daily group and the group that received 100 mg twice daily for four weeks followed by 150 mg once daily (49%, p<0.001 and 44%, p=0.006 respectively) compared to placebo (34%). Fostamatinib did not demonstrate a statistically significant difference in mTSS compared to placebo at 24 weeks for either dose (p=0.252 and p=0.170, respectively).

The safety and tolerability findings for fostamatinib observed in the OSKIRA-1 study were generally consistent with those previously reported for the TASKi Phase 2 program. The most commonly reported adverse events were typical of those seen in earlier studies, including hypertension, diarrhea, nausea, headache and nasopharyngitis (common cold).

Briggs Morrison , MD, executive vice president of Global Medicines Development and chief medical officer, said: "These top-line results provide important information on the efficacy and safety of fostamatinib and demonstrate that the compound has an effect on the signs and symptoms of rheumatoid arthritis. We will await the results of the remaining Phase 3 studies, OSKIRA-2 and OSKIRA-3, to further evaluate and characterize the profile of fostamatinib as a potential treatment for rheumatoid arthritis."

OSKIRA-1 randomized 923 patients who had experienced an inadequate response to methotrexate (MTX) a
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
2. AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis
3. Genpact and AstraZeneca Win Outsourcing Center and SSON Awards
4. AstraZeneca Acquires Neuroscience Assets From Link Medicine
5. AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimers Disease Research
6. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
7. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
8. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
9. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
10. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
11. AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 ... announced they have entered into a license and ... to target cancers. PhosImmune possesses technology ... the surfaces of tumor cells in association with ... from proteins that play a role in malignancy, ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)... , Oct. 20, 2014  Indianapolis interventional medical ... Toronto -based 3D visualization leader ... of Neurological Surgeons Annual Meeting that they have ... brain surgery. The collaboration is the first of ... to improve patient outcomes. NICO,s BrainPath® interventional access ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
... Pharmaceuticals, Inc., (NASDAQ: ACRX ) ("AcelRx"), a ... of innovative therapies for the treatment of acute and ... patent granted by the European Patent Office expired on ... that the patent has been opposed. The patent (European ...
... China, May 9, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ... a leading pharmaceutical company specializing in the development, manufacturing, ... announced today that the Company filed its annual report ... 2010 with the Securities and Exchange Commission on May ...
Cached Medicine Technology:AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period 2AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period 3
(Date:10/22/2014)... (PRWEB) October 22, 2014 Shriners Hospitals ... that will change the current location of Shriners Hospitals ... South Limestone across from the University of Kentucky Albert ... state-of-the-art ambulatory care center, owned and operated by Shriners ... orthopaedic needs of children and their families well into ...
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... During the Western United States’ worst ever ... low, Southern Oregon’s water is proving resistant to drought ... mountain snow pack on record in 2014, remain high ... That was the observation of journalist-hikers Art Bernstein and ... Oregon,” during an interview with water advocate Sharon Kleyne.† ...
(Date:10/22/2014)... Texas (PRWEB) October 22, 2014 ... of completing their continuing education at home or ... have access to 20 brand new, premium Seminar-on-Demand ... robust catalog of over 2,000 hours ... fully customize their educational experience. With such a ...
(Date:10/22/2014)... there are only 24 hours in a day, that doesn’t seem ... time within their busy schedules for exercise and fitness. Fortunately, one ... get in shape. Here are five ways you can reach your ... Up Your Commute , Consider riding a bike or taking the ... daily routine. If you must use your car to get to ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2
... Medical Center found that antiviral therapy during compensated cirrhosis, ... cost-effective approach to treating patients with advanced liver disease ... in the June issue of Liver Transplantation , ... American Association for the Study of Liver Diseases (AASLD). ...
... in study remained uninfected, but ,safe sex, still urged, experts ... are HIV-positive can lower their risk for transmitting the virus ... new research has found. , Antiretroviral drug therapy helps ... turn makes the person less infectious to others. The drugs ...
... , ... and technology solutions you can trust, proudly announces the opening of a new technology solutions ... new location, they are offering 10% off all business IT and Phoenix computer repair services ... ...
... Axendia Launches ... ... products has created unique and demanding challenges for the Life Sciences industry and the U.S. ... are preparing to take significant steps to secure the Global Supply Chain. Axendia, Inc., ...
... ... ... Nash, the Connecticut woman who made headlines after a friend,s chimpanzee brutally attacked her was ... 200-pound chimp left Nash horrifically disfigured, without her nose, lips, hands, and eyesight. After the ...
... ... and Effectiveness. , ... Charlottesville, VA, San Francisco, CA, New York, NY and Paris, France (PRWEB) May 27, ... managing Investigator Initiated Studies/ Trials (IIS/IIT). openIIS 2.5 provides a broad set of ...
Cached Medicine News:Health News:Antiviral therapy during compensated cirrhosis most cost-effective approach 2Health News:Anti-HIV Drugs May Help Prevent Spread of Virus 2Health News:my PC Techs Opens New Technology Solutions Office in Ahwatukee 2Health News:&#8220;Global Supply Chain Visibility and Security; Business Necessity, Regulatory Imperative&#8221; 2Health News:Complicated Surgeries Carry Greater Risks, Possible Need for New York Medical Malpractice Attorneys According To David Perecman 2Health News:Complicated Surgeries Carry Greater Risks, Possible Need for New York Medical Malpractice Attorneys According To David Perecman 3Health News:OpenQ Announces the Release of openIIS 2.5 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: